C12N 9/2465
Acting on alpha-galactose-glycoside bonds
Official title: {acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)}
C12N9/2465 (Acting on alpha-galactose-glycoside bonds) appears on 279 US grants and 376 published applications in this corpus.
Search patents in C12N- Granted patents
- 279
- Published applications
- 376
- Assignees
- 152
- Inventors
- 532
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 3 | 0 |
| 1977 | 0 | 0 |
| 1978 | 0 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 1 | 0 |
| 1984 | 2 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 2 | 0 |
| 1992 | 1 | 0 |
| 1993 | 2 | 0 |
| 1994 | 2 | 0 |
| 1995 | 2 | 0 |
| 1996 | 3 | 0 |
| 1997 | 4 | 0 |
| 1998 | 1 | 0 |
| 1999 | 3 | 0 |
| 2000 | 7 | 0 |
| 2001 | 9 | 2 |
| 2002 | 8 | 21 |
| 2003 | 8 | 13 |
| 2004 | 4 | 16 |
| 2005 | 6 | 10 |
| 2006 | 11 | 8 |
| 2007 | 5 | 6 |
| 2008 | 3 | 5 |
| 2009 | 7 | 9 |
| 2010 | 5 | 10 |
| 2011 | 5 | 16 |
| 2012 | 5 | 18 |
| 2013 | 11 | 15 |
| 2014 | 13 | 17 |
| 2015 | 13 | 20 |
| 2016 | 9 | 16 |
| 2017 | 14 | 9 |
| 2018 | 11 | 16 |
| 2019 | 15 | 21 |
| 2020 | 12 | 20 |
| 2021 | 19 | 17 |
| 2022 | 11 | 31 |
| 2023 | 13 | 17 |
| 2024 | 11 | 18 |
| 2025 | 13 | 15 |
| 2026 | 5 | 10 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Digital microbiology15 Sep 2026US 12,735,735 B2Bio-Rad Europe GmbH
- Compositions, devices, and methods for treating Fabry disease9 Jun 2026US 12,649,930 B2Sigilon Therapeutics, Inc.
- Compositions for the treatment of Fabry disease19 May 2026US 12,630,839 B2Sangamo Therapeutics, Inc.
- Alpha-galactosidase protein for enzyme replacement therapy (ERT) and methods of use3 Mar 2026US 12,565,643 B2The Medical College of Wisconsin, Inc.
- Compounds, devices, and uses thereof13 Jan 2026US 12,522,571 B2Sigilon Therapeutics, Inc.
- Compositions and methods for gene therapies24 Sep 2026US 2026/0286389 A1Exegenesis Bio Co.
- Recombinant adeno-associated viral vector for gene delivery3 Sep 2026US 2026/0258445 A1Abeona Therapeutics Inc.
- A method for enhancing the flavor and/or the texture of a plant-based product4 Jun 2026US 2026/0150869 A1Novozymes A/S
- Alpha-galactosidase protein for enzyme replacement therapy (ert) and methods of use28 May 2026US 2026/0146242 A1The Medical College of Wisconsin, Inc.
- Hybrid aav vector enhancing transgene expression in the liver21 May 2026US 2026/0139270 A1Genethon
Most cited
By later US patents
- mRNA for use in treatment of human genetic diseases131US 8,853,377 B2Shire Human Genetic Therapies, Inc. · 2014
- Tranfected human cells expressing human .alpha.-galactosidase A protein114US 6,083,725 ATranskaryotic Therapies, Inc. · 2000
- Coffee plant with reduced α-D-galactosidase activity110US 7,238,858 B2Nestec S. A. · 2007
- Cloning and expression of biologically active .alpha.-galactosidase A as a fusion protein85US 5,580,757 AMount Sinai School of Medicine of the City University of New York · 1996
- Cloning and expression of biologically active human .alpha.-galactosidase A79US 5,356,804 AMount Sinai School of Medicine of the City of New York · 1994